PubMed

How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?

Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DR.

Diabetes Care. 2001 Jan;24(1):45-50.PMID: 11194239 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?

Grover SA, Coupal L, Zowall H, Dorais M.

Circulation. 2000 Aug 15;102(7):722-7.PMID: 10942738 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Grover SA, Coupal L, Paquet S, Zowall H.

Arch Intern Med. 1999 Mar 22;159(6):593-600.PMID: 10090116 [PubMed - indexed for MEDLINE]Related articlesFree article

Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?

Grover S, Coupal L, Lowensteyn I.

Can J Cardiol. 2008 Dec;24(12):891-8.PMID: 19052668 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease.

Lowensteyn I, Coupal L, Zowall H, Grover SA.

J Cardiopulm Rehabil. 2000 May-Jun;20(3):147-55.PMID: 10860196 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of lipid-lowering treatment according to lipid level.

Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA.

Can J Cardiol. 2005 Jun;21(8):681-7.PMID: 16003451 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

Jönsson B, Cook JR, Pedersen TR.

Diabetologia. 1999 Nov;42(11):1293-301.PMID: 10550412 [PubMed - indexed for MEDLINE]Related articles

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention.

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H.

Arch Intern Med. 1998 Mar 23;158(6):655-62. Erratum in: Arch Intern Med 1998 Jun 8;158(11):1228. PMID: 9521231 [PubMed - indexed for MEDLINE]Related articlesFree article

The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L.

Arch Intern Med. 2003 Feb 10;163(3):333-9.PMID: 12578514 [PubMed - indexed for MEDLINE]Related articlesFree article

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.

Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L.

Intern Med. 2007;46(4):157-62. Epub 2007 Feb 15.PMID: 17301509 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

Hay JW, Sterling KL.

Pharmacoeconomics. 2005;23(2):133-41.PMID: 15748088 [PubMed - indexed for MEDLINE]Related articles

Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor.

Grover SA, Coupal L, Zowall H, Weiss TW, Alexander CM.

Am J Med. 2003 Aug 1;115(2):122-8.PMID: 12893398 [PubMed - indexed for MEDLINE]Related articles

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.

Blake GJ, Ridker PM, Kuntz KM.

Am J Med. 2003 Apr 15;114(6):485-94.PMID: 12727581 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.

Lim SS, Vos T, Peeters A, Liew D, McNeil JJ.

Med J Aust. 2001 Nov 5;175(9):459-64.PMID: 11758073 [PubMed - indexed for MEDLINE]Related articles

Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?

Grover SA, Coupal L, Kaouache M, Lowensteyn I.

Can J Cardiol. 2007 May 1;23(6):467-73.PMID: 17487292 [PubMed - indexed for MEDLINE]Related articlesFree article

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.

Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J.

Clin Ther. 2008 Aug;30(8):1508-23.PMID: 18803993 [PubMed - indexed for MEDLINE]Related articles

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.

Lamotte M, Annemans L, Evers T, Kubin M.

Pharmacoeconomics. 2006;24(2):155-69.PMID: 16460136 [PubMed - indexed for MEDLINE]Related articles

Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?

Grover SA, Coupal L, Lowensteyn I.

Can J Cardiol. 2008 Apr;24(4):261-6.PMID: 18401465 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.

Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K.

Diabetes Care. 1999 Nov;22(11):1771-8.PMID: 10546006 [PubMed - indexed for MEDLINE]Related articlesFree article